Drugs / CDH17/GUCY2C CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07152210 | Dec 2024 → Mar 2026 | colorectal cancer | Guangzhou Bio-gene Technology Co., Ltd | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDH17/GUCY2C CAR-T | “Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer” NCT07152210 ↗ |
| Modality | Cell therapy | “CDH17/GUCY2C CAR-T cell therapy” NCT07152210 ↗ |
| Route | Intravenous | “administered either intravenously or intratumorally” NCT07152210 ↗ |
| Target | CDH17 | “CDH17/GUCY2C CAR-T cell therapy” NCT07152210 ↗ |
| Target | GUCY2C | “CDH17/GUCY2C CAR-T cell therapy” NCT07152210 ↗ |